February 26, 2026— INCATE (INCubator for Antibacterial Therapies in Europe), the antimicrobial incubator supporting the advancement of early-stage anti-infective innovation, today announced a collaboration with the Cystic Fibrosis Foundation to advance research, innovation, and solutions addressing antimicrobial resistance (AMR).

People living with cystic fibrosis (CF) are particularly vulnerable to chronic and persistent bacterial infections, and the rise of antimicrobial resistance presents an increasing challenge to effective treatment. This collaboration offers strategic value in shaping the development of new anti-infective therapies and reinforces a shared commitment to addressing drug-resistant infections that pose a serious burden for the CF community.

“Antimicrobial ineffectiveness is one of the most pressing threats facing people with cystic fibrosis today,” said Holger Zimmermann, CEO of INCATE. “Our collaboration with the Cystic Fibrosis Foundation reflects a shared commitment to supporting early-stage innovators developing solutions that protect patients and enhance the effectiveness of antibacterial treatments.”

The Cystic Fibrosis Foundation is on a mission to cure cystic fibrosis and help people with CF live longer, healthier lives. By funding research, advancing specialized care, and partnering with the CF community, they are driving toward a world where no one loses their life to this disease. INCATE hopes that its relationship will enable the Foundation to further support and help shape early-stage innovation focused on addressing AMR challenges.

Through this initiative, the Cystic Fibrosis Foundation will contribute valuable scientific, clinical, and drug development expertise in chronic airway infections to INCATE’s activities. This support will help advance early-stage antibacterial projects and reinforce a shared commitment to overcoming long-standing challenges in antimicrobial innovation.

About INCATE 

INCATE is a not-for-profit partnership which brings together translational and basic research, industry, experienced entrepreneurs, and investors from across Europe and beyond. The German Center for Infection Research (DZIF), the Leibniz:HKI (part of Leibniz Association) in Germany, the Swiss National Centre of Competence in Research AntiResist, the University of Basel are the academic founding members of INCATE with the University of Basel acting as the host. Together with the four industry partners Basilea, Roche, Shionogi and MSD as well as other organizations, funders and investors, INCATE want to ensure that the pipeline of new antibiotics, antifungals and technology platforms is filled and strengthened.

For more information please contact:

helena.costa.pereira@incate.net or +49 176 46172549

www.incate.net

LinkedIn | BlueSky @INCATE